Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NICE!and 09s hit too!sgo!
nearing commercialization of key products, that's the key line there.
forget it.. i ate the ask
very thin too.. look at level 2 ask..
none do lol..mega potential here love how under radars this is too..perfect chase and kick situation for those that havent taken notice to this yet imo lol
enough for me.. how many trading under .10 have that kind of muscle at the helm??!?
i agree db! some MAJOR players involved here now all i know!
NICE! i think this one might be one that grows up someday
NEWS!GeNOsys Appoints New President
Jul 7, 2011 9:00:00 AM
Copyright Business Wire 2011
PROVO, Utah--(BUSINESS WIRE)-- GeNOsys, Inc. (OTCBB:GNYS), a medical research and development company, announced the appointment of Mr. Dale Fillmore as its President.
For the past four years, Mr. Fillmore served as President and Chief Operations Officer of a privately owned corporation with revenues in excess of $200 million per year. During this time Mr. Fillmore also served as director of the National Direct Selling Association (“DSA”). Prior to that he had worked for, and retired from, State Farm Insurance Companies, one of the largest insurance companies in the United States, after 30 years of service. During his tenure with State Farm he served in many leadership positions in Utah, Illinois and Washington. He spent the last twelve years of his career as Vice President of the Pacific Northwest - Seattle corporate office.
“As our Company is nearing commercialization of its initial products, Mr. Fillmore will be invaluable in negotiating contract agreements with manufacturers and other business partners, as well as leading the strategic planning and managing the day to day business operations as we transition from a development stage to an operating company. His wealth of experience, skills and leadership will enable us to make this transition efficiently and will enable me to devote my full effort to product development and commercialization,” stated Mr. John W.R. Miller, CEO and Chairman of the Board.
About GeNOsys:
GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas will be one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company’s Website at: www.genosysusa.com.
This press release may contain forward-looking statements including the Company’s beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company’s filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.
GeNOsys, Inc.
Keith Merrell, 801-623-4751
kmerrell@genosysusa.com
Source: GeNOsys, Inc.
----------------------------------------------
GeNOsys
Inc.Keith Merrell
801-623-4751kmerrell@genosysusa.com
yes hopefully a sign of things to come!))
i have a feeling LOTS will be talking bout GNYS sooner than later!)bring on that fda approval!
interest here last few days.. hopefully things are about to get cranking.. some pr would be nice too
g/l
love how under the radar this is too!)
i think so long as SS stays in tact and no toxic funding put in place that this could amaze when it wakes.))
im ready to see this one amaze soon!)
with the new additions to their team with major clout id say somethings going to give sooner than later here.)bring the outta nowhere BOOMage!)
chippin now.)megasleeper here imo..i want to see dollars!)
with this new addition to their team no reason it isnt possible with this sharestruct imo..he was involved in a multi billion dollar merger and on the board of amazon and a few others. This guy doesnt come onto a weee lil pennystock fer nuttin..time to get this noticed soon imo!)
right on well lets see this gem get noticed!!!!!!!!!!)
Yep It is I just love these low floaters and my board has made many big hits with them I post on
SWEET NEWS imo..GeNOsys Develops New Nitric Oxide Producing ProductsMar 8, 2011 8:00:00 AM
Copyright Business Wire 2011
PROVO, Utah--(BUSINESS WIRE)-- GeNOsys, Inc. (OTCBB:GNYS) announced that it has developed a group of nitric oxide producing products for topical use. The products support blood flow and collagen growth to injured tissue and support the healing process. The products will be available as a cream, gel or wash, depending on the desired application. Several patents have been filed related to the products and the procedures for their use. A patent application has also been filed for a nitric oxide producing product which may be used as a hand sterilizer.
“These products provide GeNOsys a significantly shorter pathway to revenue than that which can be expected from sales of our generator and nitric oxide producing medium,” stated Mr. John W.R. Miller, Chairman of the Board of GeNOsys. “We are continuing work on the generator and expect to be able to provide you with updated information on that project in the near future. We have great expectations for the positive impact our generator will have for medical treatments. We expect the cash flow generated from our topical products will fund the commercialization of the generator. We are working to introduce these products into the marketplace at the earliest date possible and expect sales to be initiated no later than the third quarter of this year.”
About GeNOsys:
GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas will be one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. The Company is currently working to establish distribution channels for its topical products. For further information, see the Company’s Website at: www.genosysusa.com.
This press release may contain forward-looking statements including the Company’s beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company’s filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.
GeNOsys, Inc.
Keith Merrell, 801-623-4751 801-623-4751
kmerrell@genosysusa.com
Source: GeNOsys, Inc.
----------------------------------------------
GeNOsys
Inc.Keith Merrell
801-623-4751 801-623-4751 kmerrell@genosysusa.com
GM all!))heres to a green week and new highs here!)lookin to add more too!)bring um! lets roll!
right on!))good thinkin imo..sleeper could wake anytime here now imo
added some 04s yesterday and today..ima keep chippin down here slow n steadily til WAKEUP time!))DF
Our current generator model is capable of delivering sufficient quantities of nitric oxide gas for individual laboratory desktop use. We will continue to further develop this and other generators and compound formulations for high production quantities and consistency. The product must have a known shelf life and be available in various configurations to produce known concentrations and known volumes of gas. Packaging is another developmental process that will need to be addressed. Management plans to rely on outside contractors to achieve these objectives.
We estimate that non-clinical laboratory sales could take place prior to the receipt of United States Food and Drug Administration (“FDA”) approval. Management anticipates that selling our generator into the market as laboratory equipment prior to receipt of final FDA approval will pave the way for sales of our medical generator and proprietary tablets, but expected financial contributions from non-medical generator and tablet sales will be too late to help offset the substantial costs of the FDA approval process for human medical uses. We expect that contributions will be able to support our manufacturing and set-up costs and contribute to the overall profitability of our Company in due time, but we believe that they will also require financing. We anticipate entering the non-clinical laboratory market in the next 4 to 6 months.(as per oct 10q so timeline wise time is near/now imo)
All human medical uses of nitric oxide gas require FDA approval, and the approval of similar international agencies. Approval can be a long and expensive process, with no assurance that any such approval will ever be granted. Management hopes to reduce time to regulatory approval by certain strategic approaches that are proprietary.
Our objectives are to establish GeNOsys (generated nitric oxide systems) as the premier nitric oxide generating pharmaceutical company, and to manufacture and sell medical grade nitric oxide generators and tablets for use in the relief of human diseases, offer value added services such as custom generators adapted for the treatment of various diseases, hire staff both currently identified and unidentified to implement our business model, and to gain FDA approval of our generating system.
this will BLAST off when gets FDA approval imo of which should be ANYtime here now as per last 10q!!!!!!!!!!
lookin alot better now imo..next wave could set it off from here me thinks!))bring it!
thoughts here at 035x045?..myself surprised its down here this low..may hit more before weeks end..if not today yet..
goin to add few more here..
im totallllly fine slowly but surely chippin away myself!)im happy adding anything in single pennies!)thoughts?
Wake up call needed today. Wonder what's up.
tryin fer some
4s..lets see um!)
donks go figure..bring um i will be lurking fer more down here in the coming days..anything under 06 me likey!)
Damn right, no sellers means we go northbound!!
no doubt lol..lets see nHOD shall we?!)
hopefully the new additions to the GNYS team bring along some friends and fam with some deep pockets fer shares here!))
Looks great. I'm glad the bid whackers got out yesterday. lol
hey Dream!)lookin great indeed 08s goin next up .11!?
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
205
|
Created
|
10/19/08
|
Type
|
Free
|
Moderators |
GeNOsys, Inc. Reports Recent Developments and Third Quarter 2008 Financial Results
PROVO, UT, Oct 16, 2008 (MARKET WIRE via COMTEX) -- GeNOsys, Inc. (OTCBB: GNYS), a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems, today announced recent key achievements and financial results for the third quarter and first nine months ended August 31, 2008.
Recent Business Development Milestones
-- Completed the research and development, engineering and construction
of the GeNOx-B and portable GeNOx-P Nitric Oxide Gas Generators. The
Company has been issued a patent on the GeNOx-B and has applied for a
patent on the GeNOx-P.
-- Completed preliminary research and development on the proprietary
tablet medium GeNOx-Tablet. Additionally, a formula for the bulk
manufacture of the tablet medium has been formulated. This formula will be
essential to carry out the business model of the Company as a commercially
viable reoccurring revenue producer of Nitric Oxide Gas Generators.
"The third quarter of fiscal 2008 was another active and productive period for GeNOsys, highlighted by the completion of the GeNOx-B and portable GeNOx-P Nitric Oxide Gas Generators," said Mr. Clark Mower, Chairman of the Board of Directors of GeNOsys. "Independent research has shown that Nitric Oxide gas, an FDA approved drug for use in the treatment of pulmonary hypertension in new-borns, may be an effective agent for the treatment of tuberculosis. Through our technology we are able to generate high purity Nitric Oxide for a significantly reduced cost. Now that we have completed this process, our plan includes a multi-track process of FDA and ISO 13485:2003 approvals in order to monetize our products.
Mr. Mower continued, "GeNOsys has a very large opportunity through the commercialization of our generators. Despite infecting nearly two billion people with the bacteria, which is one-third of the world's population, tuberculosis is "The Forgotten Plague," according to a recent article in Time magazine. The World Health Organization states that no new class of drug has been developed for its treatment in over thirty years. By 2010, the market for anti-tuberculosis drugs is projected to be between $612 and $670 million. The potential market for a new anti-tuberculosis drug is estimated to be between $316 and $345 million according to The Global Alliance for Tuberculosis Drug Development. Additionally, our research has shown that there are several other markets in which our generators have the potential to be used."
Financial results for the three months ended August 31, 2008
During the three-month period ended August 31, 2008, GeNOsys had a net loss of $332,349. This compares to a net loss of $239,738 for the comparable period ended August 31, 2007. Net loss per common share for each of the three month periods was $(.01).
Research and development ("R&D") expenses were $185,129 and $120,163, respectively, for the three-month periods ended August 31, 2008, and 2007, an increase of $64,966. The increase results from non-cash stock-based compensation charges, which were $15,488 higher in the 2008 period, from consulting and advisory board fees, and for additional work on both the nitric oxide generator and the tablet formulation to bring them to finalization. As the work on document preparation and regulatory work for FDA approval intensifies, R&D expenses are expected to increase.
General and administrative expenses were $147,152 and $122,907, respectively, for the three-month periods ended August 31, 2008 and 2007, an increase of $24,245. The increase results from the non-cash stock-based compensation charge, which was $22,287 higher in 2008 than in the comparable 2007 period. Excluding that charge, general and administrative expenses would have remained flat in 2008 as compared to 2007. General and administrative expenses are expected to continue to increase in the remaining periods of this fiscal year as expenses were incurred in raising the additional capital needed to fund our operations and bring our products to market.
Financial results for the nine months ended August 31, 2008
During the nine-month period ended August 31, 2008, GeNOsys had a net loss of $970,224. This compares to a net loss of $657,293 for the comparable period ended August 31, 2007. Net loss per common share for these periods was $(.02) and $(.01), respectively.
Research and development ("R&D") expenses were $515,832 and $319,086, respectively, for the nine-month periods ended August 31, 2008 and 2007. A significant portion of the $196,746 increase in research and development expenditures resulted from higher non-cash stock-based compensation charges in 2008, which exceeded the 2007 charge by $92,326. Increases were also seen in consulting fees and advisory board fees for additional work on both the nitric oxide generator and the tablet formulation. As the documentation preparation and regulatory work for FDA approval intensifies, R&D expenses are expected to increase.
General and administrative expenses were $456,656 and $355,396, respectively, for the nine-month periods ended August 31, 2008 and 2007. The increase results from non-cash stock-based compensation charges, which were $132,859 higher in 2008 than 2007. Excluding that charge, general and administrative expenses would have decreased by $31,599 in 2008 as compared to 2007. General and administrative expenses are expected to continue to increase in the remaining periods of this fiscal year as expenses are incurred in raising the additional capital needed to fund operations and bring the products to market.
About GeNOsys, Inc.
GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas is one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company's Website at: www.genosysusa.com.
This press release may contain forward-looking statements including the Company's beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company's filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.
GENOSYS, INC. AND SUBSIDIARIES
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
From
Beginning
of
Development
Stage
(June 30,
2005)
For the Three Months For the Nine Months To August
Ended August 31, Ended August 31, 31,
2008 2007 2008 2007 2008
----------- ----------- ----------- ----------- -----------
Revenues $ - $ - $ - $ - $ -
Cost of sales - - - - -
----------- ----------- ----------- ----------- -----------
Gross margin - - - - -
Operating
expenses:
Research and
development 185,129 120,163 515,832 319,086 1,735,288
General and
administra-
tive 147,152 122,907 456,656 355,396 1,733,279
----------- ----------- ----------- ----------- -----------
Total
operating
expenses 332,281 243,070 972,488 674,482 3,468,567
----------- ----------- ----------- ----------- -----------
Net income
(loss) from
operations (332,281) (243,070) (972,488) (674,482) (3,468,567)
----------- ----------- ----------- ----------- -----------
Other income
(expense):
Interest
income 47 3,332 2,379 17,503 82,198
Gain (loss)
on disposal
of asset - - - (414) (414)
Other income
(expense) - - - 100 100
----------- ----------- ----------- ----------- -----------
Total other
income
(expense),
net 47 3,332 2,379 17,189 81,884
----------- ----------- ----------- ----------- -----------
Net income
(loss) before
income Taxes (332,234) (239,738) (970,109) (657,293) (3,386,683)
----------- ----------- ----------- ----------- -----------
Provision
(benefit) for
income Tax 115 - 115 - 415
----------- ----------- ----------- ----------- -----------
Income (loss)
from continuing
operations (332,349) (239,738) (970,224) (657,293) (3,387,098)
Discontinued
operations:
Loss from
discontinued
operations,
net of tax - - - - (2,131)
Gain on
disposal of
discontinued
operations,
net of tax - - - - 71,253
----------- ----------- ----------- ----------- -----------
Net income
(loss) $ (332,349)$ (239,738) $ (970,224)$ (657,293)$(3,317,976)
=========== =========== =========== =========== ===========
Basic and
diluted loss
per share from
continuing
operations $ (.01)$ (.01)$ (.02)$ (.01)$ (.07)
=========== =========== =========== =========== ===========
Basic and
diluted loss
per share from
discontinued
operations $ - $ - $ - $ - $ -
=========== =========== =========== =========== ===========
Basic and
diluted loss
per share $ (.01)$ (.01)$ (.02)$ (.01)$ (.07)
=========== =========== =========== =========== ===========
Basic and
diluted
weighted
average
number of
common shares
outstanding 46,148,787 45,668,031 46,002,850 45,668,031 45,252,720
=========== =========== =========== =========== ===========
GENOSYS, INC. AND SUBSIDIARIES
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
From
Beginning
of
Development
For the Nine For the Nine Stage (June
Months Ended Months Ended 30, 2005)
August August to August
31, 2008 31, 2007 31, 2008
------------ ------------ ------------
Cash flows from operating
activities:
Net loss $ (970,224) $ (657,293) $ (3,317,976)
Adjustments to reconcile net
loss to net cash used in
operating activities:
Depreciation and amortization 38,954 34,200 97,135
Gain on the disposal of
discontinued Operations - - (71,253)
Loss on disposal of equipment - 414 414
Stock-based compensation 281,616 56,431 420,355
Decrease in cash from
discontinued operations - - (6,020)
Stock issued for services 8,536 - 278,536
Changes in operating assets
and liabilities:
(Increase) Decrease in
prepaid expenses (37,197) 64,956 (40,943)
Increase (Decrease) in
accounts payable 55,048 14,030 68,197
Increase (Decrease) in
related party liabilities (9,340) - 4,000
Increase (Decrease) in
accrued liabilities 195,522 (38,358) 209,729
Increase (Decrease) in tax
payable - - 200
------------ ------------ ------------
Net cash used in
operating activities (437,085) (525,620) (2,357,626)
------------ ------------ ------------
Cash flows from investing
activities:
Purchase of intangible assets (27,543) (33,634) (69,672)
Purchase of equipment (1,021) (18,200) (207,501)
------------ ------------ ------------
Net cash provided by
(used in) investing
Activities (28,564) (51,834) (277,173)
------------ ------------ ------------
Cash flows from financing
activities:
Issuance of common stock for
cash 153,500 - 2,574,604
Proceeds from related party
loans 36,000 - 36,000
Cash from discontinued
operations - - (19,777)
------------ ------------ ------------
Net cash provided by
financing activities 189,500 - 2,590,827
------------ ------------ ------------
Net increase (decrease) in cash (276,149) (577,454) (43,972)
Cash at beginning of the period 280,105 904,715 47,928
------------ ------------ ------------
Cash at end of the period $ 3,956 $ 327,261 $ 3,956
============ ============ ============
Supplemental Disclosure
Information
Cash paid during the year for:
Interest $ - $ - $ 750
Income/franchise taxes - - 200
Stock issued for services 8,536 - 278,536
============ ============ ============
Contact:
Alliance Advisors, LLC
Alan Sheinwald
President
(914) 669-0222
Email Contact
Mark McPartland
Vice President
(910) 686-0455
Email Contact
GeNOsys, Inc.
Michael Dancy
(801) 746-3570
Email Contact
SOURCE: GeNOsys, Inc.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |